Genomic Vision announced a collaboration with the Centre National de la Recherche Scientifique (CNRS) to launch a four-year core scientific program with the Cancer Research Center of Marseille (CRCM) for the development of companion diagnostic tests using Genomic Vision's TeloSizer® application. Telomeres are repetitive nucleotide sequences that form the ends of linear chromosomes. TeloSizer® allows for high precision measurement of telomere length and distribution to uncover links between telomere length and the onset and severity of diseases such as cancer and age-associated diseases.

New tests will be developed as part of a four-year core scientific program collaboration set up between Genomic Vision and the CRCM and will utilize Genomic Vision's DNA combing technology and TeloSizer® application. The program will employ scientific teams across the institute and will examine telomere length heterogeneity across different samples to uncover novel leukemia-specific telomere characteristics. Actionable insights from the project will be used for the development of personalize medicine approaches based on telomere morphology.

This project is part of the CRCM/IPC project supported by the OPALE Carnot Institute, a preferred partner to the healthcare Industry for research and development of innovative solutions aimed at diagnostic, treatment and follow-up of patients with leukemia, the blood cancer with the highest mortality rate, but also the leading cancer in children.